PE20001467A1 - Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina - Google Patents

Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Info

Publication number
PE20001467A1
PE20001467A1 PE2000000125A PE0001252000A PE20001467A1 PE 20001467 A1 PE20001467 A1 PE 20001467A1 PE 2000000125 A PE2000000125 A PE 2000000125A PE 0001252000 A PE0001252000 A PE 0001252000A PE 20001467 A1 PE20001467 A1 PE 20001467A1
Authority
PE
Peru
Prior art keywords
alkyl
phenylpyridine
derivatives
alcoxy
trifluoromethyl
Prior art date
Application number
PE2000000125A
Other languages
English (en)
Spanish (es)
Inventor
Quirico Branca
Michael Bos
Guido Galley
Heinz Stadler
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Thierry Godel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001467A1 publication Critical patent/PE20001467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
PE2000000125A 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina PE20001467A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (1)

Publication Number Publication Date
PE20001467A1 true PE20001467A1 (es) 2000-12-20

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000125A PE20001467A1 (es) 1999-02-24 2000-02-18 Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina

Country Status (54)

Country Link
US (2) US6297375B1 (instruction)
EP (2) EP1394150B1 (instruction)
JP (1) JP3399900B2 (instruction)
KR (1) KR100384904B1 (instruction)
CN (1) CN1142144C (instruction)
AR (2) AR029614A1 (instruction)
AT (2) ATE496032T1 (instruction)
AU (1) AU767048B2 (instruction)
BE (1) BE2015C057I2 (instruction)
BG (1) BG64554B1 (instruction)
BR (1) BRPI0000908B8 (instruction)
CA (1) CA2299139C (instruction)
CY (3) CY1111317T1 (instruction)
CZ (1) CZ300596B6 (instruction)
DE (3) DE60014216T2 (instruction)
DK (2) DK1035115T3 (instruction)
EA (1) EA003673B1 (instruction)
EG (1) EG23817A (instruction)
ES (3) ES2226622T3 (instruction)
FR (2) FR2790473B1 (instruction)
GB (1) GB2347422A (instruction)
GE (1) GEP20022676B (instruction)
GT (1) GT200000017A (instruction)
HR (2) HRP20000097B1 (instruction)
HU (1) HU227629B1 (instruction)
IL (1) IL134654A (instruction)
IS (1) IS2116B (instruction)
IT (1) IT1320763B1 (instruction)
JO (1) JO2294B1 (instruction)
LT (1) LTC1035115I2 (instruction)
LU (1) LU92745I2 (instruction)
MA (1) MA26722A1 (instruction)
ME (1) ME00593B (instruction)
MY (2) MY123648A (instruction)
NL (1) NL300758I1 (instruction)
NO (1) NO315554B1 (instruction)
NZ (1) NZ502948A (instruction)
OA (1) OA11680A (instruction)
PA (1) PA8491101A1 (instruction)
PE (1) PE20001467A1 (instruction)
PL (1) PL217311B1 (instruction)
PT (2) PT1035115E (instruction)
RS (3) RS50194B (instruction)
SE (1) SE1035115T5 (instruction)
SG (1) SG91856A1 (instruction)
SI (1) SI1035115T1 (instruction)
SK (2) SK287911B6 (instruction)
SV (1) SV2002000024A (instruction)
TN (1) TNSN00032A1 (instruction)
TR (1) TR200000520A3 (instruction)
TW (1) TWI288746B (instruction)
UA (1) UA71547C2 (instruction)
UY (1) UY32314A (instruction)
ZA (1) ZA200000894B (instruction)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3979099A (en) * 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
PL350427A1 (en) * 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 ă‚»ăƒłăƒˆăƒ©ăƒ«çĄć­æ ȘćŒäŒšç€Ÿ ć…‰ć­ŠæŽ»æ€§Î±âˆ’ăƒĄăƒăƒ«âˆ’ăƒ“ă‚čâˆ’ïŒ“ă€ïŒ•âˆ’ïŒˆăƒˆăƒȘăƒ•ăƒ«ă‚Șăƒ­ăƒĄăƒăƒ«ïŒ‰ăƒ™ăƒłă‚žăƒ«ă‚ąăƒŸăƒłăźèŁœé€ æ–čæł•
DK1303490T3 (da) * 2000-07-14 2008-08-25 Hoffmann La Roche N-oxider som NK1-receptorantagoniskprodugs af 4-phenyl-pyridinderivater
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
MXPA03005169A (es) 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.
US6531597B2 (en) * 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
BR0209151A (pt) * 2001-04-23 2004-07-13 Hoffmann La Roche Uso de antagonistas de receptor nk-1 contra hiperplasia prostĂĄtica benigna
ATE491474T1 (de) * 2001-06-07 2011-01-15 Sang Christine Dr Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
CA2457250C (en) * 2001-09-10 2010-03-30 F. Hoffmann-La Roche Ag Oily thixotropic formulations
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acĂŹclica e sulfonamida para o receptor de estrogĂȘnio
CA2508165C (en) 2002-12-06 2014-05-06 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
KR100700421B1 (ko) * 2003-01-31 2007-03-28 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ 2-(3,5-ëč„슀-íŠžëŒìŽí”ŒëŁšì˜€ëĄœë©”í‹ž-페닐)-ïŒź-[6-(1,1-닀읎옄소-1λ6-티였ëȘšíŽëŠ°-4-음)-4-(4-í”ŒëŁšì˜€ëĄœ-2-메틞-페닐)-í”ŒëŠŹë”˜-3-음]-ïŒź-메틞-ì•„ìŽì†Œë¶€í‹°ë„Žì•„ëŻžë“œì˜ ìƒˆëĄœìšŽ êČ°ì •ëł€í˜•ìČŽ
DE602004008631T2 (de) 2003-07-03 2008-07-10 F. Hoffmann-La Roche Ag Duale nk1/nk3 antagonisten zur behandlung von schizophrenie
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
WO2005011655A2 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 혾프만-띌 ëĄœìŠˆ 아êȌ ïŒźïœ‹-1 수용ìČŽ Ꞟ항제의 합성에 있얎서 쀑간ìČŽëĄœì„œì‚Źìš©ë˜ëŠ” ìčŽë„Žëł”ìŠ€ì•„ëŻžë“œ í”ŒëŠŹë”˜ 유도ìČŽì˜ ì œìĄ° ë°©ëȕ
JP2008505891A (ja) * 2004-07-06 2008-02-28 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ æČ»ç™‚è–Źăšă—ăŠăźăƒ‹ă‚łăƒăƒłă‚ąăƒŸăƒ‰èȘ˜ć°Žäœ“ăŠă‚ˆăłăă‚Œă‚‰ăźäœżç”š
EP1776342B1 (en) 2004-07-06 2011-03-02 F. Hoffmann-La Roche AG Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP4958786B2 (ja) 2004-09-20 2012-06-20 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ 耇玠環èȘ˜ć°Žäœ“ăŠă‚ˆăłæČ»ç™‚è–Źăšă—ăŠăźăă‚Œă‚‰ăźäœżç”š
EP1814551A2 (en) 2004-09-20 2007-08-08 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
WO2006034279A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
JP4958785B2 (ja) 2004-09-20 2012-06-20 ă‚ŒăƒŽăƒłăƒ»ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ 耇玠環èȘ˜ć°Žäœ“ăŠă‚ˆăłă‚čăƒ†ă‚ąăƒ­ă‚€ăƒ«âˆ’ïŒŁïœïŒĄăƒ‡ă‚”ăƒăƒ„ăƒ©ăƒŒă‚Œă‚€ăƒłăƒ’ăƒ“ă‚żăƒŒăšă—ăŠăźăă‚Œă‚‰ăźäœżç”š
CA2580844A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17ÎČ-hydroxysteroid dehydrogenase 3
US20060135636A1 (en) * 2004-11-15 2006-06-22 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
ES2329827T3 (es) * 2005-02-22 2009-12-01 F. Hoffmann-La Roche Ag Antagonistas de nk1.
CN101128428A (zh) * 2005-02-24 2008-02-20 è©čæŁźèŻäžšæœ‰é™ć…Źćž 䜜äžșé’ŸçŠ»ć­é€šé“æ‰“ćŒ€ć‰‚çš„æ–°çš„ćĄć•¶èĄç”Ÿç‰©
EP2281556A1 (en) 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
CA2602445C (en) * 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
JP5143738B2 (ja) * 2005-08-11 2013-02-13 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ćšąèƒžæ€§ç·šç¶­ç—‡è†œă‚łăƒłăƒ€ă‚Żă‚żăƒłă‚čćˆ¶ćŸĄć› ć­ăźèȘżçŻ€ç‰©èłȘ
AR058805A1 (es) 2005-09-09 2008-02-27 Smithkline Beecham Corp Derivados biciclicos de piridina utiles como agentes antipsicoticos
MY143784A (en) * 2005-09-23 2011-07-15 Hoffmann La Roche Novel dosage formulation
KR20130034062A (ko) 2005-11-08 2013-04-04 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ ïŒĄïœ”ïœ êČ°í•© ìčŽì„žíŠž ìˆ˜ì†ĄìČŽì˜ í—€í…ŒëĄœì‚ŹìŽíŽëŠ­ ìĄ°ì •ì œ
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
AU2008251504B2 (en) 2007-05-09 2013-07-18 Vertex Pharmaceuticals Incorporated Modulators of CFTR
LT3170818T (lt) 2007-12-07 2020-05-25 Vertex Pharmaceuticals Incorporated Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rĆ«gĆĄties formos
ES2406940T3 (es) * 2007-12-07 2013-06-10 Vertex Pharmaceuticals Incorporated Procedimientos para producir ĂĄcidos cicloalquilcarboxiamido-piridinabenzoicos
JP2011512413A (ja) * 2008-02-19 2011-04-21 ă‚°ăƒ©ă‚Żă‚œă‚čミă‚čă‚Żăƒ©ă‚€ăƒłăƒ»ăƒȘăƒŸăƒ†ăƒƒăƒ‰ăƒ»ăƒ©ă‚€ă‚ąăƒ“ăƒȘăƒ†ă‚Łăƒ»ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ ïŒŠïœïœ‹ăźé˜»ćźłć‰€ăšă—ăŠăźă‚ąăƒ‹ăƒȘノピăƒȘゾン
CA2716109C (en) 2008-02-28 2016-07-19 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX379946B (es) 2010-04-07 2025-03-11 Vertex Pharma Composiciones farmacéuticas de åcido 3-(6-(1-(2,2 difluorobenzo[d][1,3]dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico y su administración.
AR081069A1 (es) 2010-04-07 2012-06-06 Vertex Pharma Formas solidas del acido 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico
ES2858351T3 (es) 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producciĂłn de compuestos de cicloalquilcaraboxamido-indol
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
US20140256740A1 (en) * 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
ES2579616T3 (es) 2011-10-18 2016-08-12 Helsinn Healthcare Sa Combinaciones terapéuticas de netupitant y palonosetrón
EP2776427B1 (en) 2011-11-08 2017-02-01 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
HK1209318A1 (en) 2012-07-16 2016-04-01 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
WO2015068744A1 (ja) * 2013-11-08 2015-05-14 ă‚­ăƒƒă‚»ă‚€è–Źć“ć·„æ„­æ ȘćŒäŒšç€Ÿ ă‚«ăƒ«ăƒœă‚­ă‚·ăƒĄăƒăƒ«ăƒ”ăƒšăƒȘゾンèȘ˜ć°Žäœ“
PL3068392T3 (pl) 2013-11-12 2021-07-19 Vertex Pharmaceuticals Incorporated Proces wytwarzania kompozycji farmaceutycznych do leczenia chorób, w których poƛredniczy cftr
HUE055369T2 (hu) 2014-04-15 2021-11-29 Vertex Pharma Gyógyåszati készítmények cisztås fibrózis transzmembrån konduktancia regulåtor kövzetítette betegségek kezelésére
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 æ—„ć•†æ©˜ç”Ÿè—„ć“ć·„æ„­è‚Ąä»œæœ‰é™ć…Źćž Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
JP6494757B2 (ja) 2014-11-18 2019-04-03 ăƒăƒŒăƒ†ăƒƒă‚Żă‚č ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ïŒ¶ïœ…ïœ’ïœ”ïœ…ïœ˜   ăƒă‚€ă‚čăƒ«ăƒŒăƒ—ăƒƒăƒˆè©Šéš“é«˜é€Ÿæ¶Čäœ“ă‚Żăƒ­ăƒžăƒˆă‚°ăƒ©ăƒ•ă‚ŁăƒŒă‚’èĄŒă†ăƒ—ăƒ­ă‚»ă‚č
AU2016226006B2 (en) 2015-03-04 2021-03-04 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN105061303A (zh) * 2015-08-03 2015-11-18 æˆéƒœæŹŁæ·é«˜æ–°æŠ€æœŻćŒ€ć‘æœ‰é™ć…Źćž äž€ç§ćˆ¶ć€‡ć„ˆćŠ„ćĄćŠć…łé”źäž­é—Žäœ“n-ç”ČćŸș-4-(2-ç”ČćŸșè‹ŻćŸș)-6-(4-ç”ČćŸș-1-擌ć—ȘćŸș)-3-搥敶èƒș的新æ–čæł•
EP4019018A1 (en) 2015-09-11 2022-06-29 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
CN108368062A (zh) * 2015-12-07 2018-08-03 æ©˜ç”ŸèŻć“ć·„äžšæ ȘćŒäŒšç€Ÿ Nk1ć—äœ“æ‹źæŠ—ć‰‚
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) * 2015-12-18 2022-12-01 çŸŽć•†äșžćŸ·ćˆ©ć…‹æ–Żć…Źćž 䜜ç‚ș非慹èș«ïœ”ïœ‡ïœ’ïŒ•äżƒæ•ˆćŠ‘äč‹ç¶“ć–ä»Łäč‹ïŒ”ïŒè‹ŻćŸșćĄć•¶ćŒ–ćˆç‰©
CN106892864A (zh) * 2015-12-21 2017-06-27 äžŠæ”·ç§‘èƒœèŻç‰©ç ”ć‘æœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„çšźćŠæžžçŠ»çą±çš„æ™¶ćž‹aćŠć…¶ćˆ¶ć€‡æ–čæł•
CN115531553A (zh) 2015-12-22 2022-12-30 æ­Šç”°èŻć“ć·„äžšæ ȘćŒäŒšç€Ÿ ć†…äœ“g蛋癜-ć¶è”çš„ć—äœ“çš„äž‰éƒšćˆ†è°ƒèŠ‚ć‰‚
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
KR20250069704A (ko) 2017-06-30 2025-05-19 ìČŽìŽìŠ€ 테띌퓚틱슀 ìœ”íŹë ˆìŽì…˜ 우욞슝을 ìč˜ëŁŒí•˜êž° 위한 nk-1 êžží•­ì œ ìĄ°ì„±ëŹŒ 및 우욞슝 ìč˜ëŁŒì— ì‚Źìš©í•˜ëŠ” ë°©ëȕ
CN109384712B (zh) * 2017-08-14 2021-05-07 挗äșŹćźœćŽšćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž é¶ć‘nk1ć—äœ“æ‹źæŠ—ć‰‚ćŠć…¶ćœšćŒ–ç–—æ‰€è‡Žæ¶ćżƒă€ć‘•ćæȻ疗䞭的ćș”甚
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Novel triple combination formulations for antiemetic therapy
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
MX2020008456A (es) * 2018-09-28 2020-09-25 Vanda Pharmaceuticals Inc Uso de tradipitant para tratar la cinetosis.
WO2020132716A1 (en) * 2018-12-24 2020-07-02 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Chemical compound manufacture, new salt form, and therapeutic uses thereof
CN112174881B (zh) * 2019-07-04 2022-06-21 äžŠæ”·æŁźèŸ‰ćŒ»èŻæœ‰é™ć…Źćž äž€ç§ć„ˆćŠ„ćŒčćŠçš„èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•
KR20220050956A (ko) * 2019-08-23 2022-04-25 ìœ ìŠ€íŠžëž„ëŠŹìŠ€ 파마슈티ìčŒìŠ€ 멬믾티드 (튞레읎딩 애슈 프레슀수띌 뉮로) ìč˜ëŁŒ ë°©ëȕ 및 읎의 용도
KR20220165251A (ko) 2020-04-03 2022-12-14 넀넎 쎄띌퓚틱슀 멬믾티드 팚혈슝, 팚혈성 ì‡ŒíŹ, ꞉성 혾흡 êł€ëž€ 슝후ꔰ (ards) 또는 닀발성 Ʞꎀ Ʞ늄임애 슝후ꔰ (mods)ìœŒëĄœë¶€í„° 선택된 질환을 ìč˜ëŁŒí•˜êž° 위한 nk-1 수용ìČŽ êžží•­ì œ
US11872222B2 (en) 2020-06-02 2024-01-16 Nerre Therapeutics Limited Uses
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
KR20250125376A (ko) 2022-12-12 2025-08-21 알프레드 읎. 티펜바흐얎 êČŒì— ëȠ하 욎튞  윔. ìčŽêȌ ë„€íˆŹí”Œíƒ„íŠž 및 íŒ”ëĄœë…žì„žíŠžëĄ ì„ 포핹하는 êł ì • 용량 ëł”í•©ì œ
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에넎 위람 신규한 ìŽì†Œë¶€í‹°ëŒëŻžë“œë„˜ì˜ ì œìĄ°ë°©ëȕ
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에넎 위람 ìŽì†Œë¶€í‹°ëŒëŻžë“œ 유도ìČŽì˜ 신규한 ì œìĄ°ë°©ëȕ
EP0089765A3 (en) 1982-03-17 1984-05-23 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
WO1994003429A1 (en) 1992-07-31 1994-02-17 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CZ288176B6 (en) 1993-12-29 2001-05-16 Merck Sharp & Dohme Substituted morpholine derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical preparations in which they are comprised
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
AU693898B2 (en) 1994-06-06 1998-07-09 Warner-Lambert Company Tachykinin (NK1) receptor antagonists
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
NO309272B1 (no) * 1995-03-24 2001-01-08 Takeda Chemical Industries Ltd Cykliske forbindelser, preparater inneholdende forbindelsene samt mellomprodukter for fremstilling av forbindelsene
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
ES2214604T3 (es) 1996-03-29 2004-09-16 Pfizer Inc. Derivados de la 6-fenilpiridil-2-amina.
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
PL350427A1 (en) * 1999-02-24 2002-12-16 Hoffmann La Roche Phenyl− and pyridinyl derivatives as neurokinin 1 antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
ES2208205T3 (es) * 1999-11-29 2004-06-16 F. Hoffmann-La Roche Ag 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida.

Also Published As

Publication number Publication date
PL217311B1 (pl) 2014-07-31
BG64554B1 (bg) 2005-07-29
JO2294B1 (en) 2005-09-12
NL300758I2 (instruction) 2015-12-22
MY147451A (en) 2012-12-14
SG91856A1 (en) 2002-10-15
FR15C0049I2 (fr) 2016-02-12
EA003673B1 (ru) 2003-08-28
ES2359235T3 (es) 2011-05-19
RS50194B (sr) 2009-05-06
CY1111317T1 (el) 2015-08-05
JP3399900B2 (ja) 2003-04-21
HRP20080306B1 (hr) 2015-01-30
NO20000885L (no) 2000-08-25
BG104187A (en) 2000-11-30
KR20000062599A (ko) 2000-10-25
BR0000908B1 (pt) 2013-09-24
EA200000155A2 (ru) 2000-08-28
FR2790473A1 (fr) 2000-09-08
HRP20080306A2 (en) 2008-11-30
NO315554B1 (no) 2003-09-22
IS2116B (is) 2006-06-15
MY123648A (en) 2006-05-31
AR029614A1 (es) 2003-07-10
YU9500A (sh) 2002-11-15
CZ2000609A3 (cs) 2001-01-17
LU92745I2 (fr) 2015-08-17
EP1035115B1 (en) 2004-09-29
EP1035115A1 (en) 2000-09-13
SK2352000A3 (en) 2000-09-12
EG23817A (en) 2007-09-19
ITMI20000328A1 (it) 2001-08-23
ES2171109A1 (es) 2002-08-16
TR200000520A2 (tr) 2001-06-21
SI1035115T1 (en) 2005-02-28
TWI288746B (en) 2007-10-21
AU767048B2 (en) 2003-10-30
CY2015041I2 (el) 2016-06-22
DE60014216D1 (de) 2004-11-04
UY32314A (es) 2010-02-26
UA71547C2 (uk) 2004-12-15
CY2015042I1 (el) 2016-06-22
SE1035115T5 (sv) 2015-08-04
CY2015041I1 (el) 2016-06-22
CA2299139C (en) 2011-03-29
IL134654A0 (en) 2001-04-30
US20020091265A1 (en) 2002-07-11
NO20000885D0 (no) 2000-02-23
RS20080562A (en) 2009-09-08
MEP5709A (en) 2011-12-20
CN1142144C (zh) 2004-03-17
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
PT1394150E (pt) 2011-02-17
FR15C0049I1 (fr) 2015-08-28
AR062949A2 (es) 2008-12-17
TNSN00032A1 (fr) 2005-11-10
GB2347422A (en) 2000-09-06
US6297375B1 (en) 2001-10-02
DE60045564D1 (de) 2011-03-03
ZA200000894B (en) 2000-08-24
GB0003908D0 (en) 2000-04-05
HK1031223A1 (en) 2001-06-08
ATE496032T1 (de) 2011-02-15
CA2299139A1 (en) 2000-08-24
HUP0000748A3 (en) 2003-12-29
AU1946800A (en) 2000-08-31
NZ502948A (en) 2001-09-28
ITMI20000328A0 (it) 2000-02-23
SK287912B6 (sk) 2012-03-02
GEP20022676B (en) 2002-04-25
NL300758I1 (instruction) 2015-12-22
IL134654A (en) 2011-03-31
DE60014216T2 (de) 2006-03-02
MA26722A1 (fr) 2004-12-20
DE10008042A1 (de) 2000-08-31
PL338598A1 (en) 2000-08-28
BE2015C057I2 (instruction) 2019-03-06
ES2171109B2 (es) 2003-09-16
DK1394150T3 (da) 2011-03-21
EP1394150A1 (en) 2004-03-03
US6479483B2 (en) 2002-11-12
JP2000247957A (ja) 2000-09-12
BRPI0000908B8 (pt) 2021-05-25
CN1270959A (zh) 2000-10-25
OA11680A (fr) 2005-01-12
SK287911B6 (sk) 2012-03-02
ME00593B (me) 2015-08-31
GT200000017A (es) 2001-08-15
BR0000908A (pt) 2000-09-12
KR100384904B1 (ko) 2003-05-22
EA200000155A3 (ru) 2000-12-25
ATE277905T1 (de) 2004-10-15
SV2002000024A (es) 2002-01-23
EP1394150B1 (en) 2011-01-19
DK1035115T3 (da) 2005-01-24
HRP20000097B1 (en) 2008-12-31
IT1320763B1 (it) 2003-12-10
IS5381A (is) 2000-08-25
TR200000520A3 (tr) 2001-06-21
SE1035115T3 (sv) 2005-01-18
CZ300596B6 (cs) 2009-06-24
PT1035115E (pt) 2005-01-31
HUP0000748A2 (en) 2001-03-28
PA8491101A1 (es) 2001-04-30
HU227629B1 (en) 2011-10-28
ES2226622T3 (es) 2005-04-01
FR2790473B1 (fr) 2004-04-02
HRP20000097A2 (en) 2001-10-31
LTC1035115I2 (lt) 2017-04-10
HU0000748D0 (en) 2000-04-28

Similar Documents

Publication Publication Date Title
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
PE20050482A1 (es) Derivados de dihidrobenzofuranilo alcanamida
PE20020258A1 (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1)
PE20030238A1 (es) Uso de los antagonistas del receptor nk-1 para el tratamiento de lesiones cerebrales, espinales y neuronales
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
UY27029A1 (es) Nuevos derivados de pirazolpiridina sustituidos con piridina
DE69120100D1 (de) Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
NO20053960L (no) Piperidin-benzensulfonamidderivater
BR0306208A (pt) Compostos de dibenzilamina e seu uso farmacĂȘutico
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE106499A1 (es) Antagonistas del receptor ccr-3
AR029616A1 (es) Compuestos derivados de 3-fenil-piridina, su uso, un proceso para prepararlos y medicamentos que los contienen
AR058618A1 (es) "( indazol -5- il) - pirazinas y (1,3- dihidro- indol-2- ona) - pirazinas para el tratamiento de enfermedades y afecciones mediadas por rho quinasa
PE20000170A1 (es) Derivados benzosulfonas
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
PE20050465A1 (es) Compuestos derivados de quinuclidina como antagonistas del receptor muscarinico m3
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
PE20040772A1 (es) Composicion y actividad antiviral de derivados de piperazina azaindoloxoaceticos
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20040757A1 (es) Derivados de benzoxazina
ES2154605B1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
JO2235B1 (en) Derivatives of phenyl

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term